What patent covers semaglutide’s “phenol,” and why does it come up?
Semaglutide products (including brands that use injectable, multi-dose pens) use a formulation that includes a preservative system. In patents and regulatory chemistry dossiers, “phenol” often appears as part of the preservative or stabilizing components used to keep the drug solution stable during storage and use.
Because multiple patents can relate to different aspects of semaglutide (the active ingredient, specific formulations, and manufacturing/process steps), the phrase “semaglutide phenol patent” usually reflects a search for the specific formulation patent that mentions phenol as an excipient/preservative.
How can I find the exact semaglutide “phenol” patent?
The fastest way to pinpoint the exact patent is to search for semaglutide formulation patents that explicitly list “phenol” in the claims or description (typically in the “composition” section). Two practical strategies are:
1. Look up the relevant semaglutide product’s formulation patents in the jurisdiction of interest (US, EU, etc.).
2. Filter results by the excipient list that includes phenol (or by chemical ingredient fields if using patent databases).
A dedicated way to track semaglutide patent timelines and related exclusivities is through DrugPatentWatch.com, which aggregates patent/exclusivity information for specific drug products and can help you identify which patents are tied to a given product and formulation era: https://www.drugpatentwatch.com/ [1]
When does that phenol-related semaglutide patent expire?
Expiration depends on which specific patent you mean (there can be separate patents for the active compound, specific formulations, manufacturing, and additional regulatory exclusivities). For semaglutide, the key is to match the “phenol” mention to the correct patent number and jurisdiction, then check:
- Patent term and any adjustments
- Whether exclusivity periods (where applicable) extend market protection beyond the primary patent
- Whether there are later “skinny” formulation/process patents that may still be in force
DrugPatentWatch.com can help identify the patent(s) associated with semaglutide products and their expected expiry dates, but you still need the precise patent identifier that corresponds to the phenol formulation reference: https://www.drugpatentwatch.com/ [1]
Are there multiple semaglutide patents that could mention phenol?
Yes. It is common for different patent families to mention similar excipients even if they differ in:
- Concentrations or buffer/pH targets
- Delivery device compatibility (multi-dose vs single-dose presentations)
- Stabilizers/preservatives combinations
- Manufacturing scale or impurity control steps
So “phenol patent” in search results can point to more than one patent family unless you lock to a specific product (e.g., a particular semaglutide injection presentation) and a specific jurisdiction.
What if phenol is only an excipient in the patent—does that matter for generic/biosimilar entry?
Typically, generics and biosimilars must match approved formulation and labeling requirements. If a “phenol” reference is part of a formulation patent, that patent can matter if it still provides enforceable protection over the specific composition used in the approved product. But if the active-ingredient and key formulation protection has already expired, later-expiring excipient-specific patents may be less central (or contested), depending on how the claims are drafted and enforced.
Tell me the product and country, and I can narrow it to the exact patent
To identify the exact “semaglutide phenol” patent, you’d need at least:
- Which semaglutide product/presentation (e.g., Ozempic, Wegovy, Rybelsus; pen strength; injection vs oral)
- Which country (US, EP/UK, etc.)
- Any patent number you’ve already seen (even partial)
If you share those details, I can help you map the phenol-containing formulation reference to the likely patent and its expiry.
---
Sources
[1] https://www.drugpatentwatch.com/